|   News

Hurricane Lantus: The Storm That Will Finally Force Pharma to Take Cost-Effectiveness and Budgetary Impact Seriously

By Alex Harding, MD, MBA, Associate

“It just says ‘High.'”

I winced. My patient, a man with type 1 diabetes who had emigrated from Latin America two weeks earlier, was reading a finger prick result on his blood sugar meter to me over the phone. Normal blood sugar ranges between 70 and 100. Beyond 600, the meter loses accuracy and spits out an understated “High” instead of an actual number. I knew what this seemingly innocuous message meant: My patient was at risk for serious, even deadly complications from a critically high blood sugar. And I had known there was a chance his blood sugar would spike when I switched his insulin regimen.

Read more.


  |   Press Release

Atlas Venture Announces $250 Million Opportunity Fund

Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, today announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed fundraise. With Atlas Venture Opportunity Fund I (AVOF I), the firm will invest in existing Atlas portfolio companies as they progress.

Read more.


  |   From the Trenches

The World Cup of Conferences

Nine presentations, three press releases, forty-two satellite meetings. One conference.

This blog was written by Jason Gardner, CEO of Magenta Therapeutics and Liverpool soccer fan, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Generations: Talent Dispersion in Biotechnology

The evening of April 26, 2009, I walked from my hotel room to the nearest bar. The bar was called the Asgard, and it was on an unfamiliar road called Sidney Street, in a place I barely knew called Cambridge, Massachusetts. I wanted some comfort food before my big job interview at Millennium Pharmaceuticals the next day. I ordered a beer and burger, but as I took my first sip, a little voice in the back of my head reminded me that expensing a beer was probably not the best idea when traveling for an interview. I paid for the drink myself and stuffed the receipt into my jeans pocket.

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline

A small Cambridge, Massachusetts-based company is hoping its bet on CNS drugs using a well established pharmaceutical approach — allosteric modulators — will cement its place as a biotech powerhouse in the years to come. Cadent Therapeutics — currently a 9-person team — has already found a partner in Novartis $NVS.

Read more.